Opinion|Videos|January 29, 2025
Best Practices in Switching PBC Therapies
Panelists discuss how clinicians may transition patients to newer agents due to factors such as inadequate biochemical response, tolerability issues (particularly pruritus), or patient preference, while carefully considering the need for washout periods based on each drug's pharmacokinetics and mechanism of action.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some reasons why clinicians may consider a transition from obeticholic acid to seladelpar or elafibranor for PBC?
- Given the different mechanisms of action of obeticholic acid, seladelpar, and elafibranor, what factors should be considered in determining the need for a washout period between treatments vs direct transition?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Low-Dose Cannabinoids Show Potential to Restore Serotonin Levels and Reduce Inflammation in HIV, Study Finds
2
FDA Approves New Dosing Strength of Xolair Biosimilar, Omlyclo
3
MRD, ctDNA Testing May Help Diagnose Multiple Myeloma Precursor Conditions
4
FDA Accepts Furosemide Autoinjector sNDA for Treatment of Edema in Chronic Kidney Disease or Chronic Heart Failure
5
